ACM
CRSP icon

Asymmetry Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Asymmetry Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-37,141
Closed -$1.52M – 35
2019
Q3 		$1.52M Sell
37,141
-60,358
-62% -$2.88M 3.26% 14
2019
Q2 		$4.59M Buy
+97,499
New +$3.9M 2.49% 16

Other funds holding CRSP

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Asymmetry Capital Management's CRSP Position: Q4 2019 in Review

Asymmetry Capital Management sold out of CRISPR Therapeutics (CRSP) in Q4 2019, closing a stake of 37,141 shares — an estimated $1.52M sold.

Asymmetry Capital Management first reported a position in CRSP in Q2 2019 and held it in 2 quarters. The position peaked at $4.59M in Q2 2019. 253 funds tracked by Wall St. Rank hold CRSP as of Q4 2019.

  • Asymmetry Capital Management reported no remaining CRISPR Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Asymmetry Capital Management sold 37,141 CRISPR Therapeutics shares in Q4 2019, an estimated $1.52M.
  • Asymmetry Capital Management first reported a position in CRISPR Therapeutics in Q2 2019 and held it in 2 quarters.
  • Asymmetry Capital Management's CRISPR Therapeutics position peaked at $4.59M in Q2 2019.
  • 253 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2019.

Based on Asymmetry Capital Management's 13F filing for Q4 2019, filed 12 Feb 2020.